INSPIRED BY PATIENTS DRIVEN BY DATA
Developing therapies for Cardiovascular and Cardiometabolic disease
INSPIRED BY PATIENTS DRIVEN BY DATA
Developing therapies for Cardiovascular and Cardiometabolic disease
Transformative therapies
We are leaders in therapeutic target and drug discovery in cardiovascular and cardiometabolic disease. Our technology platforms seamlessly integrate synergistically to accelerate development of therapies to treat illnesses where no other treatments have proven effective or ever existed.
Therapy pipeline
We have a rich therapy pipeline in Cardiotoxicity, Heart failure and Hypertrophic cardiomyopathy. Strategies employed in these therapies include cellular metabolic modulation and the reactivation of cardiac regeneration.
TrueCardium®: the Platform Technology powering the Pipeline
We are at the forefront of leveraging our preclinical cardiac organoid platform (TrueCardium®) for Non-Animal Methods/New Approach Methodologies (NAM) disease modeling, Cardiotoxicity testing and Drug discovery and validation.
Genome Biologics is a resident company of Johnson & Johnson Innovation - JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.
Genome Biologics is recipient of the European Union H2020 SME Instrument Phase 1 and 2 award
Copyright © 2026 Genome Biologics – Human Cardiac Organoid Platform | TrueCardium® - All Rights Reserved.
This site uses cookies.
We use cookies to analyze website traffic and to optimize your user experience for this website. If you accept cookies, your data will be merged with that of other users.